Comparative double-blind trial of KN-7 tablet and Robaveron injection in the treatment of neurogenic bladder

37施設で, 神経因性膀胱233例を対象に, ロバベロン注射剤を標準薬とし, KN-7錠剤の経口投与による排尿障害に対する有用性を, 二重盲検群間比較試験で比較検討した.解析対象例はKN-7群108例, ロバベロン群107例である.KN-7群は1日6錠投与した.改善度の効果判定では改善以上K群40.7%, R群38.7%, やゝ改善以上それぞれ76.9%, 72.6%と有意差はなかった.臨床所見中改善の良かった項目は, 尿意, 残尿感, 尿失禁, 排尿までの時間, 排尿時間, 尿勢-排尿力と尿線中断の改善などで, これらの改善以上はK群35.8%, R群30.8%で, 有意差はなかった.副作用はK群0.9%, R群6.8%, K群が有意に少なかった.両剤とも主として下痢で, R群ではその他頭痛, 頻脈, 肝機能障害, 発熱感などを少数例認めた.臨床検査値ではGOT, GPTの上昇が2例あった.有用度有用以上はK群46.3%, R群45.8%で有意差はなかった.疾患別では, 末梢神経疾患, 膀胱の性状では弛緩性, 時期では12ヵ月以内の例で特に改善率が高かった.以上から, KN-7錠剤は, ロバベロン注射剤に比べ, 同等の効果が期待でき, 安全性も高く, 長期投与あるいは外来患者の治療にも適するThe clinical effectiveness, safety and usefulness of KN-7 tablet as a new oral application of the prostatic extract, on urinary dysfunction of neurogenic bladder were compared with those of Robaveron injection by the double-blind test method. In the study, 2 tablets t.i.d. and a shot of intramuscular injection 1 ml a day were given successively for 3 weeks. A total of 233 cases were reported from 37 facilities belonging to the KN-7 Clinical Research Group. Some of them were excluded or dropped out. The number of cases used for analysing the effectiveness, safety and usefulness were 214, 232 and 215, respectively. There was no bias between the two groups with a significant homogeneity in the background. In the overall clinical effectiveness, the effective rate including excellent, moderate and slightly effective was 76.9% with KN-7 and 77.4% with Robaveron. In the clinical usefulness, the rate of usefulness of slightly useful or above was 75.0% with KN-7 and 75.7% with Robaveron. There was no significant difference between the two groups in the clinical effective and useful rates at a significant level of 5%. Side effects were observed in 1 of the 114 (0.9%) patients given KN-7 and 8 of the 118 (6.8%) patients given Robaveron. The incidence of adverse reactions with KN-7 was significantly lower than that with Robaveron. Based on the results, it was concluded that KN-7 tablets, 2 tablets t.i.d., would be as effective and useful as a Robaveron injection 1 ml daily and safer than the latter in the treatment of neurogenic bladder

大型ヘリカル装置のIC聾アンテナと加熱特性

Ion－cyclotron heating was applied to the Large Helical Device by using single, trap loop antennas located at the outward side of the toroid. Good experimental results were obtaine with adequate plasma　confining configurations and antenna conditionings．Loading resistance of the antenna was2－8Ohm and　this was a sufficiently large value. Various heating characteristics were investigated by changing the　heating modes, ion species and magneticfield configurations．The minoriy-ion heating mode resulted in the best heating performances，and the heatin gcharacteristics largely depended on the cyclotron resonance positions．There were some unique features due to the heliotron configuration．These results showed the　effectiveness of the ICRF heating in a helical device and the appropriateness of the ICRF antenna design　in the LHD

Observation results by the TAMA300 detector on gravitational wave bursts from stellar-core collapses

We present data-analysis schemes and results of observations with the TAMA300 gravitational-wave detector, targeting burst signals from stellar-core collapse events. In analyses for burst gravitational waves, the detection and fake-reduction schemes are different from well-investigated ones for a chirp-wave analysis, because precise waveform templates are not available. We used an excess-power filter for the extraction of gravitational-wave candidates, and developed two methods for the reduction of fake events caused by non-stationary noises of the detector. These analysis schemes were applied to real data from the TAMA300 interferometric gravitational wave detector. As a result, fake events were reduced by a factor of about 1000 in the best cases. The resultant event candidates were interpreted from an astronomical viewpoint. We set an upper limit of 2.2x10^3 events/sec on the burst gravitational-wave event rate in our Galaxy with a confidence level of 90%. This work sets a milestone and prospects on the search for burst gravitational waves, by establishing an analysis scheme for the observation data from an interferometric gravitational wave detector

Therapeutic effect of Robaveron tablet (KN-7) on neurogenic bladder

Therapeutic effect of Robaveron Tablet (KN-7) was studied on 128 patients suffering from neurogenic bladder. Robaveron Tablet was administered 6 tablets daily for 3 weeks. The effect was evaluated by the residual urine, subjective symptoms, cystometric findings, urethral pressure profile and uroflowmetry. Remarkable decrease of residual urine was observed regardless of position of injury. The pressure amplitude defined as the difference between the maximum voiding pressure and the maximum resting pressure increased on any group of neurogenic bladder. The effectiveness, rated as moderately improved or better was 76.9% for brain disorders, 58.3% for upper motor neuron lesion and 75.7% for lower motor neuron lesion of spinal injuries, 58.3% for peripheral nervous injuries and 100% for others. No remarkable abnormality was observed in the results of side effects or clinical laboratory tests

Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy

前立腺肥大症103例に対しロバベロン錠の臨床効果を検討した.1日6錠, 3週間連続投与を原則とした.残尿量は病期にかかわらず減少した.収縮振幅は全病期で増加した.残尿減少率は1, 2, 3期と投与前残尿量に比例し高い伸び率を示した.膀胱内圧測定, 尿道抵抗測定と尿流量測定などからロバベロン錠の効果は膀胱利尿筋に直接作用し, 筋力の増強に寄与するためと考えた.主治医の有効性判定から, 残尿の少ない1期例に対する自覚症状の改善も期待できた.副作用はロバベロン注射剤と同種のものを数例にみ, 発現率3.9%であった.以上から, ロバベロン錠は前立腺肥大症の保存的治療薬とし, 注射剤と同等の効果が期待でき, 安全に使用できると考えたTherapeutic effect of Robaveron tablet (KN-7) was studied on 101 patients with urinary disturbance accompanied by benign prostatic hypertrophy. Robaveron tablet, which contains 20 mg of a swine prostatic extract per tablet, was administered 6 tablets daily for 3 weeks in principle. Evaluation of drug efficacy was based on residual urine, cystometric findings, urethral pressure profile, uroflowmetry and subjective symptoms. Remarkable decrease of residual urine was observed at all stages of Guyon classification, in parallel with increases of cystometric pressure amplitude and average flow rate. Rate of residual urine reduction rose in proportion to the higher stage or bulkier volume of residual urine. Improvements of subjective symptoms were also obtained. The overall effectiveness, rated slightly improved or better was 76.8%. Side effects were seen at a low rate of 3.9%, and there were no abnormal changes directly due to the drug in clinical laboratory tests. These results indicate that Robaveron tablets act on the detrusor muscle and contribute to improve the depressed voiding efficiency and incidental symptoms of the subjects

EFFECT OF ROBAVERON ON VOIDING EFFICIENCY OF NEUROGENIC BLADDER

Improvement of voiding efficiency with Robaveron was studied on 187 patients suffering from neurogenic bladder. Robaveron was administered intramuscularly for 3 weeks every day. Clinical efficiency with Robaveron was observed obviously taking the form of decrease in residual urine, obligatory ratio of residual urine and increase in bladder contractile activity. The results were discussed on three groups of neurogenic bladder; the upper motor neuron lesion type, the lower motor neuron lesion type and the patients after operation of uterine cancer. Decrease of residual urine was obtained by Robaveron in 19.6% (25.5ml), 37.0% (43.0ml) and 63.1 % (71.9ml) respectively. As to obligatory ratio of residual urine, it decreased 11.5%, 16.4% and 22.3% respectively. And as to the pressure amplitude (the difference between maximum voiding pressure and maximum resting pressure), it increased 28.3% (8.4 mmHg), 21.0% (10.4 mmHg) and 48.7% (12.7 mmHg) respectively. It was revealed by the cystometric study as well as urofiowmetric study that clinical effect of Robaveron was brought by the increase in active dynamics of detrusor muscle of urinary bladder. This clinical study showed that Robaveron is a reliable agent for improvement of voiding efficiency in neurogenic bladder, without any severe side effect including laboratory studies